CU
CURX
Curanex Pharmaceuticals Inc
$0.3332
+0.06%
$9.4M
No data for this timeframe.
Vol
Market Cap$9.4M
Cap SizeNano Cap
Inst. Holders3 funds
Inst. Value$39.8K
Inst. Activity2 buys / 0 sells
SEC Reports4
Press Releases1
Recent Activity
May 14, 2026
SEC
Curanex Pharmaceuticals provided a Q1 2026 business update highlighting preclinical progress with lead candidate Phyto-N
8-K — Impact 3/10
May 14, 2026
SEC
Curanex Pharmaceuticals provided a Q1 2026 business update focused on preclinical progress for its lead candidate Phyto-
PRESS-RELEASE — Impact 3/10
May 7, 2026
SEC
Curanex Pharmaceuticals received a 180-day extension from Nasdaq until November 2, 2026, to regain compliance with the $
8-K — Impact 5/10
Inst.
TWO SIGMA INVESTMENTS, LP — NEW
61,102 shares ($20.2K)
Inst.
RENAISSANCE TECHNOLOGIES LLC — NEW
59,297 shares ($19.6K)
May 14, 2026
earnings
Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission
<p align="center"><i>Completed GMP manufacturing and toxicology milestones supporting planned Q4 202
Mar 30, 2026
Press
Curanex Pharmaceuticals issued a press release highlighting operational progress in advancing its lead asset, Phyto-N, t
Impact 3/10
Latest Reports
NEUTRAL
8-K
3/10
Curanex Pharmaceuticals provided a Q1 2026 business update highlighting preclinical progress with lead candidate Phyto-N
May 14, 2026
NEUTRAL
PRESS-RELEASE
3/10
Curanex Pharmaceuticals provided a Q1 2026 business update focused on preclinical progress for its lead candidate Phyto-
May 14, 2026
NEUTRAL
Press
3/10
Curanex Pharmaceuticals issued a press release highlighting operational progress in advancing its lead asset, Phyto-N, t
Mar 30, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| TWO SIGMA INVESTMENTS, LP | $20.2K | NEW |
| RENAISSANCE TECHNOLOGIES LLC | $19.6K | NEW |
| BANK OF AMERICA CORP | $11.00 | — |
3 institutional holders with $39.8K total value (120,433 shares) as of 2025-Q4. Top holders: TWO, RENAISSANCE, BANK. Net buying activity: 2 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | 61,102 | $20.2K | 50.7% | NEW |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 59,297 | $19.6K | 49.2% | NEW |
| 3 | BANK OF AMERICA CORP /DE/ | 34 | $11.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | NEW | — | 61,102 | — | $20.2K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 59,297 | — | $19.6K | 2025-Q4 |
| UBS Group AG | NEW | — | 64,516 | — | $46.5K | 2025-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
4 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 4 neutral. Avg impact: 3.5/10.
NEUTRAL
8-K
3/10
Curanex Pharmaceuticals provided a Q1 2026 business update highlighting preclinical progress with le
May 14, 2026
NEUTRAL
PRESS-RELEASE
3/10
Curanex Pharmaceuticals provided a Q1 2026 business update focused on preclinical progress for its l
May 14, 2026
NEUTRAL
8-K
5/10
Curanex Pharmaceuticals received a 180-day extension from Nasdaq until November 2, 2026, to regain c
May 7, 2026
NEUTRAL
8-K
3/10
Curanex Pharmaceuticals announced an expansion of its drug development pipeline to include cancer ca
Apr 2, 2026
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 14, 2026
earnings
Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission
<p align="center"><i>Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitis</i></p>
Apr 8, 2026
other
Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline
<p align="justify"><i>Expanded case series includes advanced thymic carcinoma, small cell lung cancer, pancreatic cancer, end-stage liver cirrhosis, a
Apr 6, 2026
other
Curanex Highlights Patient Case Study Supporting Potential of Phyto-N in Cancer Cachexia and Advanced Cancer Supportive Care
<p align="center"><i>Case involving senior dosimetrist at a premier cancer hospital in the Northeast suggests potential relevance of Phyto-N in one of
Apr 2, 2026
other
Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company’s Evolution Into a Broader Therapeutics Development Company
<p align="center"><i>Company expands strategic focus into one of oncology’s </i><br><i>most urgent supportive-care challenges</i></p>
Mar 30, 2026
earnings
Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission
<p align="center"><i>Company advances manufacturing, toxicology, patent and regulatory milestones while building a broader pharmaceutical development
Mar 12, 2026
other
Curanex Expands Scientific Advisory Board With Two Distinguished Researchers
<p align="center"><i>New Appointments Bring Deep Expertise in Immunology and Infectious Disease to Advance IND Submission and Intellectual Property St